The Alteration and Clinical Significance of Th22/Th17/Th1 Cells in Patients with Chronic Myeloid Leukemia

Figure 2

Percentages of Th17, Th22, and Th1 cells in CML patients and healthy controls. (a) Percentages of PB Th22 cells from CML patients and healthy controls. Significantly decreased percentages of Th22 cells were found in ND patients compared to CP patients () or healthy controls (). (b) Percentages of BM Th22 cells from CML patients and healthy controls. Significantly decreased percentages of Th22 cells were found in ND patients compared to CP patients () or healthy controls (). (c) Percentages of Th22 cells in PB or BM of ND patients, CP patients, and healthy controls. No significant differences were found between PB and BM. (d) Percentages of Th17 cells from CML patients and healthy controls. The circulating percentages of Th17 cells were profoundly decreased in ND patients compared to CP patients () or healthy controls (). (e) The percentages of Th17 cells in BM of ND patients was proudly decreased compared to CP patients () or healthy controls (). (f) There were no differences in the percentages of Th22 cells between PB or BM in ND patients, CP patients and healthy controls. (g) Percentages of Th1 cells from CML patients and healthy controls. The percentages of Th1 cells in PB of ND patients were proudly decreased compared to CP patients () or healthy controls (). (h) The frequencies of Th1 cells in BM of ND patients, CP patients, and healthy controls. The frequency of Th1 cells in BM of ND patients was also significantly decreased compared to CP patients () or healthy controls (). (i) The percentages of Th1 cells in PB or BM were not statistically different in ND patients, CP patients, and healthy controls.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)